IP Library Granted Patent US 10,688,192
Granted Patent B2
US 10,688,192 · App. 16/280,093 · Granted Jun 23, 2020

Cleavable conjugates of antibiotics and an antibacterial cell-penetrating peptide

Inventors: Jean Anne Chmielewski (West Lafayette, IN); Mohamed Seleem (West Lafayette, IN)
Assignee: Purdue Research Foundation
A61K47/552A61K31/395A61K31/7036A61K31/7048A61K47/61A61K47/64A61K47/65
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,688,192
App. No.
16/280,093
Granted
Jun 23, 2020
Kind
B2
Abstract

The present disclosure relates to novel cleavable conjugates of antibiotics and an antibacterial cell-penetrating peptide, and methods to make and use the novel cleavable conjugates of antibiotics and an antibacterial cell-penetrating peptide.

Claims (31)

1. A method of treating a microbial infection in a patient, wherein the method comprises administering to the patient a pharmaceutical composition comprising a compound of formula:

a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, or derivative thereof,

wherein

R 1 is an antibiotic moiety;

R 2 and R 3 are each independently H, a C 1 -C 8 branched or unbranched alkyl chain, or a C 3 -C 8 cyclic alkyl;

R 4 is H, a C 1 -C 8 branched or unbranched alkyl chain, or a C 3 -C 8 cyclic alkyl;

L 3 is C 1 -C 8 branched or unbranched alkyl chain, or a C 3 -C 8 cyclic alkyl;

Z is a linker comprising a disulfide bond (S—S bond); and

n is 3-8, wherein the microbial infection is an infection caused by pathogen S. aureus, S. epidermidis, P. aeruginosa, A. baumannii, K. pneumoniae, E. faecium , enterobacteriaceae, or any combination thereof.

2. The method of claim 1 , wherein the compound is:

or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, or a derivative thereof,

wherein

R 1 is an antibiotic moiety;

R 2 and R 3 are each independently H, a C 1 -C 8 branched or unbranched alkyl chain, or a C 3 -C 8 cyclic alkyl;

R 4 is H, a C 1 -C 8 branched or unbranched alkyl chain, or a C 3 -C 8 cyclic alkyl;

L 1 , L 2 , L 3 are each independently C 1 -C 8 branched or unbranched alkyl chain, or a C 3 -C 8 cyclic alkyl;

X is O or NR 5 , wherein R 5 is H, C 1 -C 8 branched or unbranched alkyl chain, or a C 3 -C 8 cyclic alkyl, or X combined with R 1 together is an antibiotic moiety; and

n is 3-8.

3. The method of claim 1 , wherein R 1 or R 1 —X represents the moiety of an aminoglycoside antibiotics or any derivative thereof.

4. The method of claim 1 , wherein R 1 or R 1 —X represents an antibiotic moiety, wherein the antibiotic moiety is of an antibiotics selected from the group consisting of Gentamicin, Streptomycin, Kanamycin, Fradiomyctn, Paromomycin, Tobramycin, Netilmicin, Amikacin, Neomycin, Ribostamycin, Dibekacin, Sisomicin, Isepamicin, Bekanamycin, Astromicin, Plazomicin, Vancomycin, Linezolid, Erythromycin, Eperezolid, and any derivative thereof.

5. The method of claim 1 , wherein R 2 and R 3 are each independently C 1 -C 4 branched or unbranched alkyl chain.

6. The method of claim 1 , wherein R 2 and R 3 are isobutyl group.

7. The method of claim 1 , wherein R 4 is hydrogen.

8. The method of claim 2 , wherein L 1 is —(CH 2 ) 3 —, L 2 is —(CH 2 ) 3 —, and L 3 is —(CH 2 )—.

9. The method of claim 1 , wherein R 1 represents an antibiotic moiety, and the antibiotic moiety is of an antibiotics selected from the group consisting of Gentamicin, Streptomycin, Kanamycin, Fradiomyctn, Paromomycin, Tobramycin, Netilmicin, Amikacin, Neomycin, Ribostamycin, Dibekacin, Sisomicin, Isepamicin, Bekanamycin, Astromicin, Plazomicin, Vancomycin, Linezolid, Erythromycin, Eperezolid, and any derivative thereof; R 2 and R 3 are isobutyl group; R 4 is hydrogen; L 1 is —(CH 2 ) 3 —, L 2 is —(CH 2 ) 3 —, and L 3 is —(CH 2 )—; X is O; and n is 4.

10. The method of claim 2 , wherein R 1 or R 1 —X represents an aminoglycoside antibiotics moiety, and the aminoglycoside antibiotics is selected from the group consisting of Gentamicin, Kanamycin, Tobramycin, Amikacin, Neomycin, Plazomicin, and any derivative thereof; R 2 and R 3 are isobutyl group; R 4 is hydrogen; L 1 is —(CH 2 ) 3 —, L 2 is —(CH 2 ) 3 —, and L 3 is —(CH 2 )—; X is O; and n is 4.

11. The method of claim 2 , wherein R 1 or R 1 —X represents Kanamycin moiety or any derivative thereof; R 2 and R 3 are isobutyl group; R 4 is hydrogen; L 1 is —(CH 2 ) 3 —, L 2 is —(CH 2 ) 3 —, and L 3 is —(CH 2 )—; X is O; and n is 4.

12. The method of claim 1 , wherein the compound is:

a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, or a derivative thereof.

13. The method of claim 1 , wherein the microbial infection is a biofilm infection.

14. The method of claim 1 , wherein the microbial infection is an infection caused by pathogen S. aureus (ATCC 6538), S. aureus (USA400), S. epidermidis (ATCC 35984), P. aeruginosa (PAO1), P. aeruginosa (1109), A. baumannii (BAA-1605), K. pneumoniae (BAA-1706), E. faecium (ATCC 700221) or any combination thereof.

Assignments (1)
CONFIRMATORY LICENSE Recorded Sep 25, 2019
From: PURDUE UNIVERSITY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 050482/0982 →
Continuity (3)
Continuation 16050472 · Jul 31, 2018
Provisional Application 62539570 · Aug 1, 2017
Related Publication 20190175741A1 · Jun 13, 2019